drugset
drugset / Trial / NCT05274087

Study to Evaluate the Effect of Different Warm-Up Times of Risankizumab Autoinjector (AI) on the Injection Pain Experiences in Healthy Volunteers

NCT05274087 ↗

Phase 1 Completed 30 enrolled AbbVie
RandomizedParallel-groupQuadruple-blindBasic science

Summary

The objective of this study is to assess the impact of different warm-up times of risankizumab autoinjector (AI) on the participant injection site pain experience in healthy adult volunteers.

Timeline

Start
2020-09-15
Primary completion
2021-04-07
Completion
2021-04-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Risankizumab Monoclonal antibody — Subcutaneous

Indications

No indication recorded.